Lompat ke isi

Corbevax: Perbedaan antara revisi

Dari Wikipedia bahasa Indonesia, ensiklopedia bebas
Konten dihapus Konten ditambahkan
Wagino Bot (bicara | kontrib)
k →‎top: pembersihan kosmetika dasar, replaced: {{Yatim → {{orphan
 
(1 revisi perantara oleh pengguna yang sama tidak ditampilkan)
Baris 1: Baris 1:
{{Yatim|Oktober 2022}}
{{Orphan|date=Desember 2022}}
{{Infobox drug
{{Infobox drug
| Verifiedfields =
| Verifiedfields =
Baris 41: Baris 41:
}}
}}
{{COVID-19 pandemic sidebar}}
{{COVID-19 pandemic sidebar}}
'''Corbevax'''<ref>{{Cite web|last=Bharadwaj|first=Swati|date=3 June 2021|title=Telangana: Biological E starts at risk manufacturing of Corbevax|url=https://timesofindia.indiatimes.com/city/hyderabad/biological-e-starts-at-risk-manufacturing-of-corbevax/articleshow/83186640.cms|url-status=live|access-date=2021-06-03|website=The Times of India|language=en}}</ref> atau '''BioE COVID-19''', adalah sebuah kandidat [[vaksin COVID-19]] yang dikembangkan oleh Texas Children’s Hospital Center for Vaccine Development (Texas Children’s CVD) dan Baylor College of Medicine yang kemudian diberikan tanpa lisensi (gratis) ke firma biofarmasi Biological E. Limited (BioE)<ref>{{Cite web|last=Bottazzi|first=Peter J. Hotez,Maria Elena|title=A COVID Vaccine for All|url=https://www.scientificamerican.com/article/a-covid-vaccine-for-all/|website=Scientific American|language=en|access-date=2021-12-31}}</ref>. Vaksin tersebut adalah vaksin [[subunit protein]].<ref "name="CTRI/2020/11/029032>{{cite web|website=ctri.nic.in|publisher=[[Clinical Trials Registry – India|Clinical Trials Registry India]]|title=A prospective open label randomised phase-I seamlessly followed by phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E's novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease and some amount of sperm in its drug when administered intramuscularly in a two dose schedule (0, 28D) to healthy volunteers. |id=CTRI/2020/11/029032 |url=http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48329|url-status=live|archive-url=https://web.archive.org/web/20201112193905/http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48329|archive-date=12 November 2020|date=13 January 2021}}</ref><ref name="BioE1">{{cite web |title=CEPI partners with Biological E Limited to advance development and manufacture of COVID-19 vaccine candidate |url=https://cepi.net/news_cepi/cepi-partners-with-biological-e-limited-to-advance-development-and-manufacture-of-covid-19-vaccine-candidate/ |website=cepi.net |publisher=[[Coalition for Epidemic Preparedness Innovations|CEPI]] |access-date=5 March 2021}}</ref><ref name="BioE">{{cite web | vauthors = Chui M |title=Biological E. Limited and Baylor COVID-19 vaccine begins clinical trial in India |url=https://www.bcm.edu/news/biological-e-limited-and-baylor-covid-19-vaccine-begins-clinical-trial-in-india |publisher=[[Baylor College of Medicine]] |date=16 November 2020 | name-list-style=vanc}}</ref><ref name="a">{{cite news | vauthors = Leo L |title= Biological E initiates human trials of vaccine |url=https://www.livemint.com/news/india/biological-e-starts-human-trials-of-baylor-college-s-covid-19-vaccine-11605525030199.html |work=Mint |date=16 November 2020 | name-list-style=vanc}}</ref> Pemerintah India l Drugs Controller General of India (DCGI) telah memberikan persetujuan untuk penggunaannya di India (Emergency Use Authorization atau EUA).<ref>{{Cite web|title=Texas Children’s Hospital and Baylor College of Medicine Covid-19 Vaccine Technology Secures Emergency Use Authorization in India {{!}} Texas Children's Hospital|url=https://www.texaschildrens.org/texas-children%E2%80%99s-hospital-and-baylor-college-medicine-covid-19-vaccine-technology-secures-emergency|website=www.texaschildrens.org|access-date=2021-12-31}}</ref> Corbevax juga telah diberikan hak produksi secara gratis ke beberapa perusahaan di negara-negara berkembang lainnya, termasuk ke perusahaan Biofarma di Indonesia <ref>{{Cite web|title=Texas Children's Hospital and Baylor College of Medicine Host Signing Ceremony with Biofarma and Indonesian Delegation in Attendance {{!}} Texas Children's Hospital|url=https://www.texaschildrens.org/about-us/news/releases/texas-childrens-hospital-and-baylor-college-medicine-host-signing-ceremony-biofarma-and-indonesian|website=www.texaschildrens.org|language=en|access-date=2022-01-03}}</ref><ref>{{Cite web|title=https://twitter.com/peterhotez/status/1437125474384322563|url=https://twitter.com/peterhotez/status/1437125474384322563|website=Twitter|language=id|access-date=2021-12-31}}</ref>
'''Corbevax'''<ref>{{Cite web|last=Bharadwaj|first=Swati|date=3 June 2021|title=Telangana: Biological E starts at risk manufacturing of Corbevax|url=https://timesofindia.indiatimes.com/city/hyderabad/biological-e-starts-at-risk-manufacturing-of-corbevax/articleshow/83186640.cms|url-status=live|access-date=2021-06-03|website=The Times of India|language=en}}</ref> atau '''BioE COVID-19''', adalah sebuah kandidat [[vaksin COVID-19]] yang dikembangkan oleh Texas Children’s Hospital Center for Vaccine Development (Texas Children’s CVD) dan Baylor College of Medicine yang kemudian diberikan tanpa lisensi (gratis) ke firma biofarmasi Biological E. Limited (BioE)<ref>{{Cite web|last=Bottazzi|first=Peter J. Hotez,Maria Elena|title=A COVID Vaccine for All|url=https://www.scientificamerican.com/article/a-covid-vaccine-for-all/|website=Scientific American|language=en|access-date=2021-12-31}}</ref>. Vaksin tersebut adalah vaksin [[subunit protein]].<ref "name="CTRI/2020/11/029032>{{cite web|website=ctri.nic.in|publisher=[[Clinical Trials Registry – India|Clinical Trials Registry India]]|title=A prospective open label randomised phase-I seamlessly followed by phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E's novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease and some amount of sperm in its drug when administered intramuscularly in a two dose schedule (0, 28D) to healthy volunteers. |id=CTRI/2020/11/029032 |url=http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48329|url-status=live|archive-url=https://web.archive.org/web/20201112193905/http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48329|archive-date=12 November 2020|date=13 January 2021}}</ref><ref name="BioE1">{{cite web |title=CEPI partners with Biological E Limited to advance development and manufacture of COVID-19 vaccine candidate |url=https://cepi.net/news_cepi/cepi-partners-with-biological-e-limited-to-advance-development-and-manufacture-of-covid-19-vaccine-candidate/ |website=cepi.net |publisher=[[Coalition for Epidemic Preparedness Innovations|CEPI]] |access-date=5 March 2021}}</ref><ref name="BioE">{{cite web | vauthors = Chui M |title=Biological E. Limited and Baylor COVID-19 vaccine begins clinical trial in India |url=https://www.bcm.edu/news/biological-e-limited-and-baylor-covid-19-vaccine-begins-clinical-trial-in-india |publisher=[[Baylor College of Medicine]] |date=16 November 2020 | name-list-style=vanc}}</ref><ref name="a">{{cite news | vauthors = Leo L |title= Biological E initiates human trials of vaccine |url=https://www.livemint.com/news/india/biological-e-starts-human-trials-of-baylor-college-s-covid-19-vaccine-11605525030199.html |work=Mint |date=16 November 2020 | name-list-style=vanc}}</ref> Pemerintah India l Drugs Controller General of India (DCGI) telah memberikan persetujuan untuk penggunaannya di India (Emergency Use Authorization atau EUA).<ref>{{Cite web|title=Texas Children’s Hospital and Baylor College of Medicine Covid-19 Vaccine Technology Secures Emergency Use Authorization in India {{!}} Texas Children's Hospital|url=https://www.texaschildrens.org/texas-children%E2%80%99s-hospital-and-baylor-college-medicine-covid-19-vaccine-technology-secures-emergency|website=www.texaschildrens.org|access-date=2021-12-31}}</ref> Corbevax juga telah diberikan hak produksi secara gratis ke beberapa perusahaan di negara-negara berkembang lainnya, termasuk ke perusahaan Biofarma di Indonesia <ref name="texaschildrens.org">{{Cite web|title=Texas Children's Hospital and Baylor College of Medicine Host Signing Ceremony with Biofarma and Indonesian Delegation in Attendance {{!}} Texas Children's Hospital|url=https://www.texaschildrens.org/about-us/news/releases/texas-childrens-hospital-and-baylor-college-medicine-host-signing-ceremony-biofarma-and-indonesian|website=www.texaschildrens.org|language=en|access-date=2022-01-03}}</ref><ref>{{Cite web|title=https://twitter.com/peterhotez/status/1437125474384322563|url=https://twitter.com/peterhotez/status/1437125474384322563|website=Twitter|language=id|access-date=2021-12-31}}</ref>


== Referensi<ref name="texaschildrens.org"/> ==
== Referensi<ref>{{Cite web|title=Texas Children's Hospital and Baylor College of Medicine Host Signing Ceremony with Biofarma and Indonesian Delegation in Attendance {{!}} Texas Children's Hospital|url=https://www.texaschildrens.org/about-us/news/releases/texas-childrens-hospital-and-baylor-college-medicine-host-signing-ceremony-biofarma-and-indonesian|website=www.texaschildrens.org|language=en|access-date=2022-01-03}}</ref> ==
{{reflist}}
{{reflist}}


Baris 53: Baris 53:
{{COVID-19}}
{{COVID-19}}


[[Kategori:vaksin Covid-19 India]]
[[Kategori:Vaksin Covid-19 India]]





Revisi terkini sejak 12 Februari 2023 23.02

Deskripsi vaksin
Penyakit target SARS-CoV-2
Jenis Subunit protein
Data klinis
Nama dagang Corbevax
Kat. kehamilan ?
Status hukum ?
Rute Intraotot
Pengenal
Kode ATC Tidak ada

Corbevax[1] atau BioE COVID-19, adalah sebuah kandidat vaksin COVID-19 yang dikembangkan oleh Texas Children’s Hospital Center for Vaccine Development (Texas Children’s CVD) dan Baylor College of Medicine yang kemudian diberikan tanpa lisensi (gratis) ke firma biofarmasi Biological E. Limited (BioE)[2]. Vaksin tersebut adalah vaksin subunit protein.[3][4][5][6] Pemerintah India l Drugs Controller General of India (DCGI) telah memberikan persetujuan untuk penggunaannya di India (Emergency Use Authorization atau EUA).[7] Corbevax juga telah diberikan hak produksi secara gratis ke beberapa perusahaan di negara-negara berkembang lainnya, termasuk ke perusahaan Biofarma di Indonesia [8][9]

  1. ^ Bharadwaj, Swati (3 June 2021). "Telangana: Biological E starts at risk manufacturing of Corbevax". The Times of India (dalam bahasa Inggris). Diakses tanggal 2021-06-03. 
  2. ^ Bottazzi, Peter J. Hotez,Maria Elena. "A COVID Vaccine for All". Scientific American (dalam bahasa Inggris). Diakses tanggal 2021-12-31. 
  3. ^ "A prospective open label randomised phase-I seamlessly followed by phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E's novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease and some amount of sperm in its drug when administered intramuscularly in a two dose schedule (0, 28D) to healthy volunteers". ctri.nic.in. Clinical Trials Registry India. 13 January 2021. CTRI/2020/11/029032. Diarsipkan dari versi asli tanggal 12 November 2020. 
  4. ^ "CEPI partners with Biological E Limited to advance development and manufacture of COVID-19 vaccine candidate". cepi.net. CEPI. Diakses tanggal 5 March 2021. 
  5. ^ Chui M (16 November 2020). "Biological E. Limited and Baylor COVID-19 vaccine begins clinical trial in India". Baylor College of Medicine. 
  6. ^ Leo L (16 November 2020). "Biological E initiates human trials of vaccine". Mint. 
  7. ^ "Texas Children's Hospital and Baylor College of Medicine Covid-19 Vaccine Technology Secures Emergency Use Authorization in India | Texas Children's Hospital". www.texaschildrens.org. Diakses tanggal 2021-12-31. 
  8. ^ a b "Texas Children's Hospital and Baylor College of Medicine Host Signing Ceremony with Biofarma and Indonesian Delegation in Attendance | Texas Children's Hospital". www.texaschildrens.org (dalam bahasa Inggris). Diakses tanggal 2022-01-03. 
  9. ^ "https://twitter.com/peterhotez/status/1437125474384322563". Twitter. Diakses tanggal 2021-12-31.  Hapus pranala luar di parameter |title= (bantuan)

Pranala luar

[sunting | sunting sumber]



Templat:Vaccine-stub